Cover Image
Market Research Report

Asia Pacific Cephalosporin Drugs Market (2019-2025)

Published by KBV Research Product code 906241
Published Content info 123 Pages
Delivery time: 1-2 business days
Price
Back to Top
Asia Pacific Cephalosporin Drugs Market (2019-2025)
Published: July 31, 2019 Content info: 123 Pages
Description

The Asia Pacific Cephalosporin Drugs Market would witness market growth of 2.73% CAGR during the forecast period (2019-2025).

Growth in population incidence with pneumonia, tonsillitis, bronchitis, and gonorrhea drives market growth. Increased R&D activities are expected to create extremely effective & secure medicines, increased use of combination therapies boost market development, and increased pneumonia, tonsillitis, bronchitis, & gonorrhea occurrence. These aforementioned factors help in accelerating the share of the global Cephalosporin Drugs market.

Manufacturers are engaged in the creation of new anti-microbial resistance drugs. The resistance mechanism has described the complexity and variety of the need for new and enhanced B-lactam antibiotics. The firms are also engaged in the strategic growth of new products, such as Shionogi & Co in 2017. Ltd has been working with the F. Hoffmann-La Roche Ltd to develop and commercialize baloxavir marboxi.

Based on Generation, the market is segmented into First-Generation Cephalosporin, Second-Generation Cephalosporin, Third-Generation Cephalosporin, Fourth-Generation Cephalosporin, and Fifth-Generation Cephalosporin. Based on Application, the market is segmented into Respiratory Tract Infection, Skin Infection, Ear Infection, Sexually Transmitted Infection and Others. Based on Route of Administration, the market is segmented into Injections and Oral Drugs. Based on Type, the market is segmented into Branded and Generic. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include ABBOTT Laboratories, Teva Pharmaceuticals Industries Ltd., Johnson and Johnson, GlaxoSmithKline PLC (GSK), Pfizer, Inc., Merck & Co., Inc., Bayer AG, Baxter International, Inc., Bristol-Myers Squibb Company and Novartis AG.

Scope of the Study

Market Segmentation:

By Generation

  • First-Generation Cephalosporin
  • Second-Generation Cephalosporin
  • Third-Generation Cephalosporin
  • Fourth-Generation Cephalosporin
  • Fifth-Generation Cephalosporin

By Application

  • Respiratory Tract Infection
  • Skin Infection
  • Ear Infection
  • Sexually Transmitted Infection
  • Others

By Route of Administration

  • Injections
  • Oral Drugs

By Type

  • Branded
  • Generic

By Country

  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific

Companies Profiled:

  • ABBOTT Laboratories
  • Teva Pharmaceuticals Industries Ltd.
  • Johnson and Johnson
  • GlaxoSmithKline PLC (GSK)
  • Pfizer, Inc.
  • Merck & Co., Inc.
  • Bayer AG
  • Baxter International, Inc.
  • BRISTOL-MYERS SQUIBB COMPANY
  • Novartis AG

Unique Offerings from KBV Research:

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free
Table of Contents

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 Asia Pacific Cephalosporin Drugs Market, by Generation
    • 1.4.2 Asia Pacific Cephalosporin Drugs Market, by Application
    • 1.4.3 Asia Pacific Cephalosporin Drugs Market, by Route of Administration
    • 1.4.4 Asia Pacific Cephalosporin Drugs Market, by Type
    • 1.4.5 Asia Pacific Cephalosporin Drugs Market, by Country
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. Asia Pacific Cephalosporin Drugs Market by Generation

  • 3.1 Asia Pacific First-Generation Cephalosporin Drugs Market by Country
  • 3.2 Asia Pacific Second-Generation Cephalosporin Drugs Market by Country
  • 3.3 Asia Pacific Third-Generation Cephalosporin Drugs Market by Country
  • 3.4 Asia Pacific Fourth-Generation Cephalosporin Drugs Market by Country
  • 3.5 Asia Pacific Fifth-Generation Cephalosporin Drugs Market by Country

Chapter 4. Asia Pacific Cephalosporin Drugs Market by Application

  • 4.1 Asia Pacific Respiratory Tract Infection Market by Country
  • 4.2 Asia Pacific Skin Infection Market by Country
  • 4.3 Asia Pacific Ear Infection Market by Country
  • 4.4 Asia Pacific Sexually Transmitted Infection Market by Country
  • 4.5 Asia Pacific Others Market by Country

Chapter 5. Asia Pacific Cephalosporin Drugs Market by Route of Administration

  • 5.1 Asia Pacific Injections Market by Country
  • 5.2 Asia Pacific Oral Drugs Market by Country

Chapter 6. Asia Pacific Cephalosporin Drugs Market by Type

  • 6.1 Asia Pacific Branded Market by Country
  • 6.2 Asia Pacific Generic Market by Country

Chapter 7. Asia Pacific Cephalosporin Drugs Market by Country

  • 7.1 China Cephalosporin Drugs Market
    • 7.1.1 China Cephalosporin Drugs Market by Generation
    • 7.1.2 China Cephalosporin Drugs Market by Application
    • 7.1.3 China Cephalosporin Drugs Market by Route of Administration
    • 7.1.4 China Cephalosporin Drugs Market by Type
  • 7.2 Japan Cephalosporin Drugs Market
    • 7.2.1 Japan Cephalosporin Drugs Market by Generation
    • 7.2.2 Japan Cephalosporin Drugs Market by Application
    • 7.2.3 Japan Cephalosporin Drugs Market by Route of Administration
    • 7.2.4 Japan Cephalosporin Drugs Market by Type
  • 7.3 India Cephalosporin Drugs Market
    • 7.3.1 India Cephalosporin Drugs Market by Generation
    • 7.3.2 India Cephalosporin Drugs Market by Application
    • 7.3.3 India Cephalosporin Drugs Market by Route of Administration
    • 7.3.4 India Cephalosporin Drugs Market by Type
  • 7.4 South Korea Cephalosporin Drugs Market
    • 7.4.1 South Korea Cephalosporin Drugs Market by Generation
    • 7.4.2 South Korea Cephalosporin Drugs Market by Application
    • 7.4.3 South Korea Cephalosporin Drugs Market by Route of Administration
    • 7.4.4 South Korea Cephalosporin Drugs Market by Type
  • 7.5 Singapore Cephalosporin Drugs Market
    • 7.5.1 Singapore Cephalosporin Drugs Market by Generation
    • 7.5.2 Singapore Cephalosporin Drugs Market by Application
    • 7.5.3 Singapore Cephalosporin Drugs Market by Route of Administration
    • 7.5.4 Singapore Cephalosporin Drugs Market by Type
  • 7.6 Malaysia Cephalosporin Drugs Market
    • 7.6.1 Malaysia Cephalosporin Drugs Market by Generation
    • 7.6.2 Malaysia Cephalosporin Drugs Market by Application
    • 7.6.3 Malaysia Cephalosporin Drugs Market by Route of Administration
    • 7.6.4 Malaysia Cephalosporin Drugs Market by Type
  • 7.7 Rest of Asia Pacific Cephalosporin Drugs Market
    • 7.7.1 Rest of Asia Pacific Cephalosporin Drugs Market by Generation
    • 7.7.2 Rest of Asia Pacific Cephalosporin Drugs Market by Application
    • 7.7.3 Rest of Asia Pacific Cephalosporin Drugs Market by Route of Administration
    • 7.7.4 Rest of Asia Pacific Cephalosporin Drugs Market by Type

Chapter 8. Company Profiles

  • 8.1 ABBOTT Laboratories
    • 8.1.1 Company Overview
    • 8.1.2 Financial Analysis
    • 8.1.3 Segmental and Regional Analysis
    • 8.1.4 Research & Development Expense
    • 8.1.1 Recent strategies and developments:
      • 8.1.1.1 Collaborations, partnerships and agreements:
      • 8.1.1.2 Acquisition and Mergers:
  • 8.2 Teva Pharmaceutical Industries Ltd.
    • 8.2.1 Company Overview
    • 8.2.2 Financial Analysis
    • 8.2.3 Regional Analysis
    • 8.2.4 Research & Development Expenses
    • 8.2.5 Recent strategies and developments:
      • 8.2.5.1 Product launches:
  • 8.3 Johnson and Johnson
    • 8.3.1 Company Overview
    • 8.3.2 Financial Analysis
    • 8.3.3 Segmental &Regional Analysis
    • 8.3.4 Research & Development Expenses
    • 8.3.5 Recent strategies and developments:
      • 8.3.5.1 Acquisition and Mergers:
  • 8.4 GlaxoSmithKline PLC (GSK)
    • 8.4.1 Company Overview
    • 8.4.2 Financial Analysis
    • 8.4.3 Segmental and Regional Analysis
    • 8.4.4 Research & Development Expense
    • 8.4.5 Recent strategies and developments:
      • 8.4.5.1 Collaborations, partnerships and agreements:
      • 8.4.5.2 Expansion:
      • 8.4.5.3 Approval:
  • 8.5 Pfizer, Inc.
    • 8.5.1 Company Overview
    • 8.5.2 Financial Analysis
    • 8.5.3 Segmental and Regional Analysis
    • 8.5.4 Research & Development Expense
    • 8.5.5 Recent strategies and developments:
      • 8.5.5.1 Collaborations, partnerships and agreements:
      • 8.5.5.2 Product launches:
      • 8.5.5.3 Acquisition and Mergers:
  • 8.6 Merck & Co., Inc.
    • 8.6.1 Company Overview
    • 8.6.2 Financial Analysis
    • 8.6.3 Segmental and Regional Analysis
    • 8.6.4 Research & Development Expenses
    • 8.6.5 Recent strategies and developments:
      • 8.6.5.1 Collaborations, partnerships and agreements:
      • 8.6.5.2 Product launches:
  • 8.7 Bayer AG (Bayer Schering Pharma AG)
    • 8.7.1 Company Overview
    • 8.7.2 Financial Analysis
    • 8.7.3 Segmental and Regional Analysis
    • 8.7.4 Research & Development Expense
    • 8.7.5 Recent strategies and developments:
      • 8.7.5.1 Collaborations, partnerships and agreements:
      • 8.7.5.2 Product launches:
  • 8.8 Baxter International, Inc.
    • 8.8.1 Company Overview
    • 8.8.2 Financial Analysis
    • 8.8.3 Regional Analysis
    • 8.8.4 Research & Development Expense
    • 8.8.5 Recent strategies and developments:
      • 8.8.5.1 Product launches:
  • 8.9 Bristol-Myers Squibb Company
    • 8.9.1 Company overview
    • 8.9.2 Financial Analysis
    • 8.9.3 Regional Analysis
    • 8.9.4 Research & Development Expense
    • 8.9.5 Recent strategies and developments:
      • 8.9.5.1 Collaborations, partnerships and agreements:
  • 8.1 Novartis AG
    • 8.10.1 Company Overview
    • 8.10.2 Financial Analysis
    • 8.10.3 Segmental and Regional Analysis
    • 8.10.4 Research & Development Expense
    • 8.10.5 Recent strategies and developments:
      • 8.10.5.1 Product launches:
      • 8.10.5.2 Acquisition and Mergers:

LIST OF TABLES

  • TABLE 1 ASIA PACIFIC CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION
  • TABLE 2 ASIA PACIFIC CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION
  • TABLE 3 ASIA PACIFIC CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION
  • TABLE 4 ASIA PACIFIC CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION
  • TABLE 5 ASIA PACIFIC FIRST-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 6 ASIA PACIFIC FIRST-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 7 ASIA PACIFIC SECOND-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 8 ASIA PACIFIC SECOND-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 9 ASIA PACIFIC THIRD-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 10 ASIA PACIFIC THIRD-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 11 ASIA PACIFIC FOURTH-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 12 ASIA PACIFIC FOURTH-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 13 ASIA PACIFIC FIFTH-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 14 ASIA PACIFIC FIFTH-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 15 ASIA PACIFIC CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
  • TABLE 16 ASIA PACIFIC CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
  • TABLE 17 ASIA PACIFIC RESPIRATORY TRACT INFECTION MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 18 ASIA PACIFIC RESPIRATORY TRACT INFECTION MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 19 ASIA PACIFIC SKIN INFECTION MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 20 ASIA PACIFIC SKIN INFECTION MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 21 ASIA PACIFIC EAR INFECTION MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 22 ASIA PACIFIC EAR INFECTION MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 23 ASIA PACIFIC SEXUALLY TRANSMITTED INFECTION MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 24 ASIA PACIFIC SEXUALLY TRANSMITTED INFECTION MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 25 ASIA PACIFIC OTHERS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 26 ASIA PACIFIC OTHERS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 27 ASIA PACIFIC CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION
  • TABLE 28 ASIA PACIFIC CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION
  • TABLE 29 ASIA PACIFIC INJECTIONS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 30 ASIA PACIFIC INJECTIONS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 31 ASIA PACIFIC ORAL DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 32 ASIA PACIFIC ORAL DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 33 ASIA PACIFIC CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION
  • TABLE 34 ASIA PACIFIC CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION
  • TABLE 35 ASIA PACIFIC BRANDED MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 36 ASIA PACIFIC BRANDED MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 37 ASIA PACIFIC GENERIC MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 38 ASIA PACIFIC GENERIC MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 39 ASIA PACIFIC CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 40 ASIA PACIFIC CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 41 CHINA CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION
  • TABLE 42 CHINA CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION
  • TABLE 43 CHINA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION
  • TABLE 44 CHINA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION
  • TABLE 45 CHINA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
  • TABLE 46 CHINA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
  • TABLE 47 CHINA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION
  • TABLE 48 CHINA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION
  • TABLE 49 CHINA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION
  • TABLE 50 CHINA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION
  • TABLE 51 JAPAN CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION
  • TABLE 52 JAPAN CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION
  • TABLE 53 JAPAN CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION
  • TABLE 54 JAPAN CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION
  • TABLE 55 JAPAN CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
  • TABLE 56 JAPAN CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
  • TABLE 57 JAPAN CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION
  • TABLE 58 JAPAN CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION
  • TABLE 59 JAPAN CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION
  • TABLE 60 JAPAN CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION
  • TABLE 61 INDIA CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION
  • TABLE 62 INDIA CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION
  • TABLE 63 INDIA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION
  • TABLE 64 INDIA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION
  • TABLE 65 INDIA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
  • TABLE 66 INDIA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
  • TABLE 67 INDIA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION
  • TABLE 68 INDIA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION
  • TABLE 69 INDIA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION
  • TABLE 70 INDIA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION
  • TABLE 71 SOUTH KOREA CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION
  • TABLE 72 SOUTH KOREA CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION
  • TABLE 73 SOUTH KOREA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION
  • TABLE 74 SOUTH KOREA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION
  • TABLE 75 SOUTH KOREA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
  • TABLE 76 SOUTH KOREA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
  • TABLE 77 SOUTH KOREA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION
  • TABLE 78 SOUTH KOREA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION
  • TABLE 79 SOUTH KOREA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION
  • TABLE 80 SOUTH KOREA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION
  • TABLE 81 SINGAPORE CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION
  • TABLE 82 SINGAPORE CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION
  • TABLE 83 SINGAPORE CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION
  • TABLE 84 SINGAPORE CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION
  • TABLE 85 SINGAPORE CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
  • TABLE 86 SINGAPORE CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
  • TABLE 87 SINGAPORE CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION
  • TABLE 88 SINGAPORE CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION
  • TABLE 89 SINGAPORE CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION
  • TABLE 90 SINGAPORE CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION
  • TABLE 91 MALAYSIA CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION
  • TABLE 92 MALAYSIA CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION
  • TABLE 93 MALAYSIA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION
  • TABLE 94 MALAYSIA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION
  • TABLE 95 MALAYSIA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
  • TABLE 96 MALAYSIA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
  • TABLE 97 MALAYSIA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION
  • TABLE 98 MALAYSIA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION
  • TABLE 99 MALAYSIA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION
  • TABLE 100 MALAYSIA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION
  • TABLE 101 REST OF ASIA PACIFIC CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION
  • TABLE 102 REST OF ASIA PACIFIC CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION
  • TABLE 103 REST OF ASIA PACIFIC CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION
  • TABLE 104 REST OF ASIA PACIFIC CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION
  • TABLE 105 REST OF ASIA PACIFIC CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
  • TABLE 106 REST OF ASIA PACIFIC CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
  • TABLE 107 REST OF ASIA PACIFIC CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION
  • TABLE 108 REST OF ASIA PACIFIC CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION
  • TABLE 109 REST OF ASIA PACIFIC CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION
  • TABLE 110 REST OF ASIA PACIFIC CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION
  • TABLE 111 KEY INFORMATION - ABBOTT LABORATORIES
  • TABLE 112 KEY INFORMATION - TEVA PHARMACEUTICALS INDUSTRIES LTD.
  • TABLE 113 KEY INFORMATION -JOHNSON AND JOHNSON
  • TABLE 114 KEY INFORMATION - GLAXOSMITHKLINE PLC (GSK)
  • TABLE 115 KEY INFORMATION - PFIZER, INC.
  • TABLE 116 KEY INFORMATION - MERCK & CO., INC.
  • TABLE 117 KEY INFORMATION - BAYER AG
  • TABLE 118 KEY INFORMATION - BAXTER INTERNATIONAL, INC.
  • TABLE 119 KEY INFORMATION - BRISTOL-MYERS SQUIBB COMPANY
  • TABLE 120 KEY INFORMATION - NOVARTIS AG

LIST OF FIGURES

  • FIG 1 METHODOLOGY FOR THE RESEARCH
Back to Top